Innovative Updates to the Brevera® Breast Biopsy System with CorLumina® Imaging Technology Are Introduced by Hologic

Hologic, Inc. an innovative medical technology company primarily focused on improving women’s health, today announced improvements to the Brevera® Breast Biopsy System with CorLumina® Imaging Technology, the world’s first and only breast biopsy solution to combine vacuum-assisted tissue acquisition, real-time imaging verification and advanced post-biopsy handling in one, integrated system.

Since its launch in 2017, the Brevera system has shifted the way clinicians perform breast biopsies and verify that the targeted tissue samples have been acquired. The system streamlines the entire biopsy process from start to finish – with real-time imaging for verification of sample acquisition and automated post-biopsy specimen handling.  These integrated features offer the potential to save facilities an average of 13 minutes per procedure2 to transform the patient experience and enhance workflow. In addition, they allow clinicians to remain by the patient’s side during the entire procedure, eliminating the need to leave the room to image and verify tissue samples, which often leads to lengthy procedure times and anxious patients, as well as interruptions to facility screening schedules.

“As a world leader in breast health, we take great pride in our commitment to constant innovation – informed by clinical research and customer feedback – to continuously expand and improve upon the performance of our products,” said Jennifer Meade, Hologic’s Division President, Breast and Skeletal Health Solutions. “The launch of the Brevera system represented a major transformation in breast biopsy, and we’re confident that the improvements we’ve introduced will further the system’s ability to enhance workflow, increase accuracy and improve the overall patient experience.”

To better meet clinician needs, the Brevera system features a reusable device driver and disposable needles to simplify storage and improve waste management.1 The system also features improvements that allow radiologists and technologists to better separate and verify target samples automatically, then transfer seamlessly to pathology with minimal handling to help maintain core integrity.

The Brevera system is designed for use with Hologic’s Affirm® Prone biopsy guidance system. When paired together, the Brevera system and Affirm® system accelerate the speed and efficiency of prone biopsy procedures to further reduce the patient’s time under compression.[2]


References:

[1] Compared to Eviva® device. Hologic Data on file 2017.

2 Brevera Pulse Survey, Quantitative report. Inspired Insights. April 2019

[2] Results from, “A Prospective, Block Stratified Clinical Trial to Evaluate the Performance and Operation of the Brevera® Breast Biopsy System” (NCT03300206) (US)

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The new CT 5300 system is already installed at several European hospitals and has been well-received. “CT 5300 offers CT imaging from head to toe, combined with high-end functionality such as coronary angiography, delivering an extremely broad spectrum of applications, helping us to better manage increased volumes of patients,” said Dr. Hilmar Kühl, Head of Radiology at St. Bernhard-Hospital Kamp-Lintfort, Germany. “With this latest system from Philips, we see an improvement in image quality with Precise Imaging, and for the first time, we can now visualize cardiac anatomy by using Precise Cardiac nearly artifact-free, which is very valuable to help improve cardiac care for our patients.”
“Working closely with leading interventionists, we designed the latest Azurion neuro biplane to meet their requirements of superior patient care, optimized angio suite performance, and efficient return on investment.  Together, I am confident we can continue to reduce the impact of stroke, helping more patients to recover faster and reducing long-term impact on their health," said Mark Stoffels, Business Leader of Image Guided Therapy Systems at Philips.
LumiGuide, powered by Fiber Optic RealShape (FORS) technology, enables doctors to navigate through blood vessels using light, instead of X- ray. “[It’s] one of the most exciting changes that we’ve seen with imaging certainly throughout my career,” said Andres Schanzer, Vascular Surgeon, at UMass Memorial Medical Center, Worcester, MA, USA.
Carestream Health notes twenty-seven of the patents were awarded by the U.S. Patent and Trademark Office; an additional 43 patents were received in European and Asian countries.
According to an Insightec study, patients experienced significant reductions in upper limb tremor, tremor-related disability, and quality of life. The most common intraprocedural adverse events included dizziness, headache, nausea, and vomiting, which all resolved. Post-procedural adverse events included paraesthesia and gait disturbance, which were often transient or resolved within 12 months.

By using this website you agree to accept Medical Device News Magazine Privacy Policy